Serhat Inaloz H, Ozturk Savas, Akcali Cenk, Kirtak Necmettin, Tarakcioglu Mehmet
Department of Dermatology, School of Medicine, Gaziantep University, Gaziantep, Turkey.
J Dermatol. 2008 May;35(5):276-82. doi: 10.1111/j.1346-8138.2008.00466.x.
The present study aimed to evaluate the effectiveness of 2.5 mg/kg/day cyclosporin (CsA) treatment in patients with severe chronic idiopathic urticaria (CIU) and the impact of CsA treatment on several cytokines involved in the etiopathogenesis of CIU. Twenty-seven CIU patients and 24 healthy control subjects were included in the study. The autologous serum skin test (ASST) for autoantibodies and urticaria activity scoring (UAS) were measured for the evaluation of the clinical severity and the response to therapy, and the serum levels of interleukin (IL)-6, IL-8, IL-2 receptor, IL-1beta, tumor necrosis factor (TNF)-alpha and IL-5 were measured. The mean UAS score was 32.07 +/- 7.05 and 6.22 +/- 3.84 before and after CsA treatment, respectively. The serum IL-2 receptor, TNF-alpha and IL-5 levels of patients before CsA treatment were statistically higher than those of the control group (P = 0.001), and after 4 weeks of CsA therapy the mean IL-2R, TNF-alpha and IL-5 levels were significantly decreased. The data from this study demonstrate that CsA therapy is efficient and safe for CIU patients. Increase in clinical efficacy and marked decreases in serum cytokine levels suggest that inhibition of cytokine generation is involved in the action of the drug in this clinical setting.
本研究旨在评估2.5mg/kg/天环孢素（CsA）治疗重度慢性特发性荨麻疹（CIU）患者的有效性以及CsA治疗对CIU发病机制中几种细胞因子的影响。该研究纳入了27例CIU患者和24例健康对照者。通过检测自身抗体的自体血清皮肤试验（ASST）和荨麻疹活动度评分（UAS）来评估临床严重程度和对治疗的反应，并检测血清白细胞介素（IL）-6、IL-8、IL-2受体、IL-1β、肿瘤坏死因子（TNF）-α和IL-5水平。CsA治疗前后的平均UAS评分分别为32.07±7.05和6.22±3.84。CsA治疗前患者的血清IL-2受体、TNF-α和IL-5水平在统计学上高于对照组（P = 0.001），CsA治疗4周后，平均IL-2R、TNF-α和IL-5水平显著降低。本研究数据表明，CsA治疗对CIU患者有效且安全。临床疗效的提高和血清细胞因子水平的显著降低表明，在这种临床情况下，抑制细胞因子生成参与了该药物的作用。
